// App-Quantinova.ai

: Long-Term Safety and Efficacy of Pegcetacoplan Treatment in Adults with Paroxysmal Nocturnal Hemoglobinuria

Researchers

Presenter

  • Christopher J. Patriquin

Principal Investigators

  • Andrija Bogdanovic

  • Morag Griffin

  • Richard Kelly

  • Jaroslaw P. Maciejewski

  • Brian Mulherin

  • Regis Peffault de Latour

  • Alexander Roeth

  • Veena Selvaratnam

  • Jeffrey Szer

  • Jessica Savage

  • Regina Horneff

  • Lisa Tan

  • Michael Yeh

  • Jens Panse

Medical Centers

  • Assistance Publique-Hôpitaux de Paris, Saint-Louis Hospital, Université Paris Cité, Paris, France

  • Hematology & Apheresis Medicine, University Health Network, Toronto General Hospital, Toronto, Canada

  • Hematology Oncology Of Indiana, Indianapolis, IN

  • Clinic of Hematology, Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Belgrade, Serbia

  • Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, Essen, Germany

  • French Reference Center for Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria, Paris, France

  • Ascension St. Vincent Carmel, Carmel, IN

  • Department of Hematology, Ampang Hospital, Ampang, Malaysia

  • Department of Clinical Haematology, The Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, Australia

  • Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Aachen, Germany

  • Department of Haematology, St James University Hospital, Leeds, United Kingdom

  • Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

  • Swedish Orphan Biovitrum AB, Stockholm, Sweden

  • Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen, Germany

Locations

  • France

  • United States

  • Malaysia

  • Germany

  • Canada

  • Australia

  • Sweden

  • Serbia

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Paroxysmal nocturnal hemoglobinuria

Biomarkers

  • Lactate dehydrogenase

Drug/Treatment

  • Eculizumab

Outcome

  • N/A


Study Design

  • Efficacy

  • Safety

  • Open Label

  • Multicenteric

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A